INSERM UMR 911, Centre de Recherche en Oncologie Biologique et en Oncopharmacologie, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France.
Biochem Pharmacol. 2012 Aug 15;84(4):432-43. doi: 10.1016/j.bcp.2012.05.010. Epub 2012 May 23.
Invasion of normal brain tissue by tumor cells is a major contributing factor to the recurrence of glioblastoma and its resistance to therapy. Here, we have assessed the efficacy of the microtubule (MT) targeting agent Epothilone B (patupilone) on glioblastoma cell migration, a prerequisite for invasive tumor cell behavior. At non-cytotoxic concentrations, patupilone inhibited glioblastoma cell movement, as shown by transwell cell migration, random motility and spheroid assays. This anti-migratory effect was associated with a reduced accumulation of EB1 and other MT plus end tracking proteins at MT ends and with the induction of MT catastrophes, while the MT growth rate and other MT dynamic instability parameters remained unaltered. An increase in MT catastrophes led to the reduction of the number of MTs reaching the leading edge. Analysis of the effect of patupilone on MT dynamics in a reconstituted in vitro system demonstrated that the induction of MT catastrophes and an alteration of EB1 accumulation at MT plus end are intrinsic properties of patupilone activity. We have thus demonstrated that patupilone antagonizes glioblastoma cell migration by a novel mechanism, which is distinct from suppression of MT dynamic instability. Taken together, our results suggest that EB proteins may represent a new potential target for anti-cancer therapy in highly invasive tumors.
肿瘤细胞侵入正常脑组织是导致胶质母细胞瘤复发及其对治疗产生耐药性的一个主要因素。在这里,我们评估了微管(MT)靶向药物埃博霉素 B(帕他泊汀)对胶质母细胞瘤细胞迁移的疗效,细胞迁移是侵袭性肿瘤细胞行为的一个前提。在非细胞毒性浓度下,帕他泊汀抑制胶质母细胞瘤细胞的运动,这可通过 Transwell 细胞迁移、随机运动和球体实验来证明。这种抗迁移作用与 EB1 和其他 MT 末端追踪蛋白在 MT 末端的积累减少以及 MT 灾难的诱导有关,而 MT 生长速度和其他 MT 动态不稳定性参数保持不变。MT 灾难的增加导致到达前沿的 MT 数量减少。在体外重建系统中分析帕他泊汀对 MT 动力学的影响表明,MT 灾难的诱导和 MT 末端 EB1 积累的改变是帕他泊汀活性的固有特性。因此,我们证明了帕他泊汀通过一种新的机制拮抗胶质母细胞瘤细胞的迁移,这种机制与抑制 MT 动态不稳定性不同。总之,我们的结果表明,EB 蛋白可能代表高度侵袭性肿瘤中癌症治疗的一个新的潜在靶点。